Chinese antibody maker, famed for Ebola cocktail, notches $160M as it focuses on cancer, autoimmune drugs
Big name investors have come together to bring Chinese biotech Mabworks’ Series C haul to $160 million, boosting a biologics pipeline that spans a number of cancers and autoimmune diseases.
Mabworks made an appearance on the international stage back in 2015 for its role in manufacturing an Ebola antibody that was used to treat two patients. That drug, MIL77, remains one of three drugs touted on the front page of the company’s website; the other two are antibodies that target HER2 and CD20, respectively.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.